Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gastric Cancer

  Free Subscription

Articles published in
Eur J Cancer
    July 2022
  1. QUAAS A, Biesma HD, Wagner AD, Verheij M, et al
    Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
    Eur J Cancer. 2022;173:95-104.
    >> Share

  2. KIM CG, Hong M, Jeung HC, Lee G, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2022;172:387-399.
    >> Share

    May 2022
  3. KROESE TE, van Laarhoven HWM, Nilsson M, Lordick F, et al
    Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
    Eur J Cancer. 2022;166:254-269.
    >> Share

    April 2022
  4. ZHOU Y
    Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial.
    Eur J Cancer. 2022 Apr 10. pii: S0959-8049(22)00142.
    >> Share

    March 2022
  5. KOBAYSHI K, Suyama K, Katsuya H, Izawa N, et al
    A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701.
    Eur J Cancer. 2022;166:279-286.
    >> Share

  6. MOORE JL, Kumar S, Santaolalla A, Patel PH, et al
    Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    Eur J Cancer. 2022;163:180-188.
    >> Share

    February 2022
  7. LORENZEN S, Thuss-Patience P, Pauligk C, Gokkurt E, et al
    FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric
    Eur J Cancer. 2022;165:48-57.
    >> Share

    October 2021
  8. VAN VELZEN MJM, Pape M, Dijksterhuis WPM, Slingerland M, et al
    The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer.
    Eur J Cancer. 2021;156:60-69.
    >> Share

    September 2021
  9. HE X, Gu Y, Cao Y, Hu B, et al
    Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
    Eur J Cancer. 2021;157:114-123.
    >> Share

    April 2021
  10. DEGIULI M, Reddavid R, Tomatis M, Ponti A, et al
    D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.
    Eur J Cancer. 2021;150:10-22.
    >> Share

    March 2021
  11. RIVERA F, Izquierdo-Manuel M, Garcia-Alfonso P, Martinez de Castro E, et al
    Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Eur J Cancer. 2021;145:158-167.
    >> Share

    December 2020
  12. PARK S, Nam CM, Kim SG, Mun JE, et al
    Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
    Eur J Cancer. 2020;144:49-60.
    >> Share

    November 2020
  13. DIJKSTERHUIS WPM, Verhoeven RHA, Pape M, Slingerland M, et al
    Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
    Eur J Cancer. 2020;139:107-118.
    >> Share

    September 2020
  14. ATHAUDA A, Nankivell M, Langley RE, Alderson D, et al
    Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
    Eur J Cancer. 2020;137:45-56.
    >> Share

    August 2020
  15. GIULIANI J, Bonetti A
    Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
    Eur J Cancer. 2020;138:77-79.
    >> Share

  16. BANG YJ, Golan T, Dahan L, Fu S, et al
    Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Eur J Cancer. 2020;137:272-284.
    >> Share

    May 2020
  17. NISHIKAWA K, Murotani K, Fujitani K, Inagaki H, et al
    Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TR
    Eur J Cancer. 2020;132:159-167.
    >> Share

  18. VAN DER KAAIJ RT, Koemans WJ, van Putten M, Snaebjornsson P, et al
    A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
    Eur J Cancer. 2020;130:23-31.
    >> Share

  19. ZHENG Y, Yang X, Yan C, Feng R, et al
    Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Eur J Cancer. 2020;130:12-19.
    >> Share

    April 2020
  20. KAWAZOE A, Yamaguchi K, Yasui H, Negoro Y, et al
    Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Eur J Cancer. 2020;129:97-106.
    >> Share

    March 2020
  21. SLAGTER AE, Tudela B, van Amelsfoort RM, Sikorska K, et al
    Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial.
    Eur J Cancer. 2020;130:146-154.
    >> Share

    February 2020
  22. LIU X, Cao Y, Li R, Gu Y, et al
    Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
    Eur J Cancer. 2020;128:27-37.
    >> Share

    January 2020
  23. VAN CUTSEM E, Muro K, Cunningham D, Bodoky G, et al
    Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Eur J Cancer. 2020;127:150-157.
    >> Share

  24. WAGNER AD, Lordick F, Grabsch HI, Terashima M, et al
    Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
    Eur J Cancer. 2020;124:67-76.
    >> Share

    November 2019
  25. THOMAS A, Virdee PS, Eatock M, Lord SR, et al
    Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
    Eur J Cancer. 2019;124:131-141.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016